Mesoblast (MESO) Return on Sales (2014 - 2023)

Mesoblast (MESO) posted Return on Sales of 0.12% for Q2 2023, down 23.49% sequentially from 0.1% in Q1 2023, and down 2.0% YoY from 0.12% in Q2 2022.

Mesoblast (MESO) Return on Sales (2014 - 2023) Analysis & Trends

Mesoblast has reported Return on Sales for 10 years, with the latest figure at 0.12% in Q2 2023.

Quarterly Return on Sales fell 2.0% year-over-year to 0.12% in Q2 2023, while the trailing twelve-month figure through Jun 2023 was 0.1% (down 1.0% YoY) and the FY2025 annual result came in at 0.06%, up 9.0% from the prior year.
Return on Sales slipped to 0.12% in Q2 2023 per MESO's latest filing, from 0.1% in the prior quarter.
Over five years, Return on Sales peaked at 0.01% in Q2 2020 and troughed at 0.22% in Q1 2019.
A 5-year average of 0.1% and a median of 0.1% in 2022 frame the typical range for Return on Sales.
The sharpest annual moves came in 2019 and 2020: Return on Sales rose 15 bps in 2019, then decreased 16 bps in 2020.
Over 5 years, Return on Sales stood at 0.11% in 2019, then declined by 1 bps to 0.11% in 2020, then soared by 36 bps to 0.07% in 2021, then slumped by 56 bps to 0.11% in 2022, then dropped by 3 bps to 0.12% in 2023.
According to Business Quant data, Return on Sales over the past three periods registered 0.12%, 0.1%, and 0.11% for Q2 2023, Q1 2023, and Q4 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.00%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	0.00%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.00%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	0.00%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.00%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	0.00%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.00%
10	Mesoblast	2.01 Bn	1.87 Bn	-	-

Download Data